Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Fenretinide

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7148-8

Synonyms

Definition

Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR) is a synthetic analogue of all-trans retinoic acid (ATRA; vitamin A) that shows promise both as a chemotherapeutic and chemopreventive agent in a variety of tumor types. Its anticancer actions are attributed to apoptosis induction.

Characteristics

Fenretinide is a synthetic derivative of ATRA that was synthesized by R.W. Johnson Pharmaceuticals, USA, in the late 1960s. Sporn and colleagues assessed its biological activity and discovered that fenretinide accumulated in the breast rather than the liver. In 1979, the first report of fenretinide acting as an anticancer agent was published where it inhibited chemically induced breast cancer in rats. Subsequently, numerous studies have investigated the use of fenretinide as both a chemotherapeutic and chemopreventive agent.

Fenretinide differs from ATRA as the carboxyl functional group is replaced by an amide-linked 4-hydroxyphenyl...

Keywords

Ovarian Cancer Chemopreventive Agent Delay Tumor Growth Night Blindness Chemoprevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, Guerrieri-Gonzaga A (2012) Fenretinide (4-HPR): a preventive chance for women at risk of genetic and familial risk? J Biomed Biotechnol. doi:10.1155/2012/172897Google Scholar
  2. Hail N Jr, Kim HJ, Lotan R (2006) Mechanisms of fenretinide-induced apoptosis. Apoptosis 11:1677–1694CrossRefPubMedGoogle Scholar
  3. Sogno I, Vene R, Ferrari N, De Censi A, Imperatori A, Noonan DM, Tosetti F, Albini A (2010) Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol 75:2–14CrossRefPubMedGoogle Scholar

Copyright information

© © Crown Copyright 2012

Authors and Affiliations

  1. 1.Gray Institute for Radiation Oncology and Biology, Department of OncologyUniversity of OxfordOxfordUK